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http://www.biomedcentral.com/1471-230X/14/185RESEARCH ARTICLE Open AccessMELD score and antibiotics use are predictors of
length of stay in patients hospitalized with
hepatic encephalopathy
Valérie Martel-Laferrière1,2*, Caitlin Homberger1, Kian Bichoupan1 and Douglas T Dieterich1Abstract
Background: Hepatic encephalopathy (HE) represents a significant burden to the healthcare system. The aim of
this study was to determine factors influencing the hospital length of stay among patients hospitalized with HE.
Methods: A data warehouse query was performed to identify 316 patients with a first hospitalization during which
HE occurred, between April 2010 and February 2012. Baseline and hospitalization characteristics were collected with
IRB approval. A negative binomial multivariable model was used to control for potential confounders on the length
of hospitalization.
Results: Median age was 59 years, and 60.4% of admitted patients were male. The median MELD score was 22
(IQR: 17-28). Median length of stay was 8 days (IQR: 3.25-14.25). After controlling for MELD score, female gender
(2.2 days; p = 0.04), being initially admitted for a reason other than HE (liver-related: 7.6 days; p < 0.01 and non
liver-related 10.7 days; p < 0.01) and receiving antibiotics other than rifaximin (10.5 days; p < 0.01) were associated
with longer length of stay whereas hepatitis C (-3.1 days; p < 0.01) was associated with a shorter length of stay.
Conclusions: MELD score, gender, use of antibiotics other than rifaximin, reason for admission and hepatitis C are
predictors readily available in clinic that can help identify patients at risk for longer length of stay.
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Hepatic encephalopathy (HE) is a common complication of
chronic liver disease, occurring in 30-45% of patients with
cirrhosis [1,2]. Hepatic encephalopathy is a spectrum of
neuropsychiatric manifestations ranging from psychomotor
difficulties to altered consciousness and even coma [3].
Each year HE is responsible for 0.33% of all hospitaliza-
tions, due to the susceptibility of a large population of
persons with chronic liver disease, which comprises some
5.5 million people in the United States alone [2,4]. HE is
an expensive disease. Among hepatitis C (HCV) infected
patients, HE costs are estimated at $16,430 for the first
year and $3,810 in the subsequent years [5]. For those* Correspondence: valerie.martel-laferriere.chum@ssss.gouv.qc.ca
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article, unless otherwise stated.requiring hospitalization, length of stay is long, lasting
8.5 days on average, and costs approximately $63,000 per
case [2]. HE-related hospitalizations are responsible for
approximately 7.2 billion dollars in direct costs annually
[2]. Fuelled by the aging of the HCV population and the
growing incidence of non-alcoholic fatty liver disease,
recent trends in the costs of HE-related hospitalization
will likely continue.
To better understand the factors underlying the up-
ward trend of hospitalizations and associated costs, this
retrospective chart review investigates the length of stay
of patients hospitalized with hepatic encephalopathy at a
large academic tertiary care center.Methods
This is a retrospective chart-review study conducted at
Mount Sinai Medical Center, a large tertiary care center.
The Icahn School of Medicine at Mount Sinai Institu-
tional Review Board approved the study (GCO #12-0998).d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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encephalopathy was collected through a query of the elec-
tronic medical record using the ICD-9 codes 570.X, 572.2,
348.3, 348.31, 348.39 and 291.2. The charts of identified
patients were reviewed to confirm study eligibility. Pa-
tients included were adults hospitalized between April 1st
2010 and February 28th 2012 for hepatic encephalopathy
or for which hospitalization for another reason was com-
plicated by hepatic encephalopathy. Children with hepatic
encephalopathy and adults with metabolic encephalopathy
unrelated to liver diseases were excluded. One event per
patient was recorded. If more than one event occurred,
the first event during the study period was recorded. Data
were collected from electronic discharge summaries that
included a full history, a list of interventions, lab results,
medication profiles and discharge orders.
Patients could present with more than one baseline
liver disease. HE hospitalizations were those for which
HE was one of the primary diagnoses in the discharge
summary. Liver-related hospitalizations were those for
which a cirrhosis complication such as ascites or vari-
ceal bleeding was the primary diagnosis whereas non
liver-related hospitalizations encompassed a large array
of reasons of hospital admission such as infection or
trauma. HE was not part of the primary diagnosis, but
occurred during the hospitalization when the patient
was categorized as “liver-related” or “non-liver related”.
Length of stay was calculated from the day of admission
to the day of discharge. If the patient was transferred
from another hospital, the days spent in the other
hospital were also counted. Thirty-day readmissions were
calculated from the day of discharge. Patients who died
during the first admission were excluded from the re-
admission analysis. Model for End-Stage Liver Disease
(MELD) score used was the crude MELD score based only
on laboratory values (creatinine, International Normalized
Ratio (INR) and bilirubin). Choice of treatment was up to
the discretion of the clinician as Mount Sinai hospital does
not have an HE protocol.
Descriptive statistics were used to investigate the out-
comes of hospitalization. Factors influencing the length
of hospitalization were identified with a univariable
negative binomial regression model. A negative binomial
regression was used due to over dispersion. All factors
assessed were selected a priori. To control for potential
confounders on the length of hospitalization, a multivar-
iable negative binomial regression model was built. All
variables with a p-value of <0.10 in univariable analysis
were assessed in a multivariable model. Variables with a
p-value less than 0.05 were retained in the final model.
A second negative binomial model that excluded pa-
tients who died during the hospitalization, was created.
A p-value less than 0.05 was considered statistically sig-
nificant. Data were analyzed in SAS version 9.3.Results
Baseline characteristics
The medical record query lead to the identification of
502 potential patients, of which 316 were confirmed to
fit the inclusion criteria after chart review. The main rea-
sons for exclusion were: age <18, or hospitalization for
metabolic encephalopathy not related to liver disease.
Table 1 presents the baseline characteristics of the
patients. The median age was 59 (IQR: 53-65), more
patients were male than female (191, 60.4%) and a third
were Caucasian (107, 33.9%). MELD scores were high
with a median of 22 (IQR: 17-28). Hepatitis C was the
most common underlying liver condition (110 patients,
35%) followed by alcohol (98, 31%). Only 15 patients
(4.7%) had a transjugular intrahepatic portosystemic
shunt (TIPS). For more than half the cohort, the
hospitalization recorded was not the first episode of HE
(161/289; 55.7%).
Hepatic encephalopathy was the main reason for hos-
pital admission for 198 patients (62.7%). Of the remaining
patients, 88 patients (27.8%) were hospitalized for a liver-
related reason and 30 patients (9.5%) for a non liver-
related reason. A small number of patients had acute
hepatitis (32; 10.1%) or spontaneous bacterial peritonitis
(34; 10.8%) during the hospitalization. Most patients
received a combination of rifaximin and lactulose (240;
75.9%).
Hospitalization outcomes
Sixty-six patients (20.9%) died during the initial
hospitalization. Of the 250 patients discharged from
their first hospitalization, 96 (38.4%) were readmitted
within 30 days and an additional 34 patients were
readmitted between 31 and 90 days for a total of 130
patients (52%) readmitted within 90 days. Overall, only
38% of the patients had a favourable outcome after
their initial admission, meaning they did not die in the
hospital or were not readmitted within 90-days.
Predictors of length of hospitalization
The median length of stay was 8 days (IQR: 3.3-14.8 days),
but the data contained outliers such as one hospitalization
of 113 days. The median length of stay for various sub-
groups can be seen in Table 2. In univariable analysis,
females, patients with acute hepatitis, patients with no
prior history of HE or TIPS, and patients who required
antibiotics other than rifaximin were more likely to have a
longer length of hospitalization (Table 3). The baseline
liver disease and the reason for admission also signifi-
cantly influenced the duration of hospitalization.
In multivariable analysis, we found the change in
length of stay to be associated with female gender
(2.2 days; p = 0.04), primary reason of hospitalization
other than HE (liver-related: 7.6 days; p < 0.01 and non
Table 1 Baseline and hospitalization characteristics
Patients characteristics N = 316
Age, median (IQR) 59 (53-65)
Gender (male; %) 191 (60.4%)
Race (%)
• Caucasian 107 (33.9%)
• African American 42 (13.3%)
• Asian 15 (4.7%)
• Hispanic 91 (28.8%)
• Unknown 61 (19.3%)
Baseline liver disease (%)
• Hepatitis B 10 (3.2%)
• Hepatitis C 110 (35%)
• Alcohol 98 (31%)
• Non-alcoholic fatty liver disease 31 (10%)
• Autoimmune hepatitis 10 (3%)
• Primary biliary cirrhosis/Primary
sclerosing cholangitis
10 (3%)
• Hemochromatosis 6 (2%)
• Post-liver complication 9 (3%)
• Cryptogenic/unspecified 58 (19%)
Presence of TIPS (%) 15 (4.7%)
Prior history of HE (%) 161/289 (55.7%)
MELD, median (IQR) 22 (17-28)
Primary reason of admission
• HE 198 (62.7%)
• Liver related-complication 88 (27.8%)
• Non-liver related 30 (9.5%)
Acute hepatitis (%) 32 (10.1%)
Treatment
• Lactulose alone 61 (19.3%)
• Lactulose + rifaximin 240 (75.9%)
• Rifaximin alone 10 (3.2%)
• Othera 5 (1.6%)
Use of antibiotics other than rifaximin
during the admission (%)
181 (57.3%)
Length of stay, days, median (IQR) 8 (3.25-14.75)
aMetronidazole, neomycin, supportive
Table 2 Length of hospitalization















> 40 10.5 (5.5-24.5)
Hepatitis B 7.5 (2.0 – 11.0)
Hepatitis C 5.0 (3.0 -10.0)
Alcohol 9.0 (4.0 – 17.0)
Non-alcoholic fatty liver disease 7.0 (4.0 – 15.0)
Autoimmune hepatitis 11.5 (8.0 – 17.0)
PBC/PSC 7.5 (2.0 – 20.0)
Hemochromatosis 10.5 (10.0 – 11.0)
Post-liver transplant complication 12.0 (5.0 – 13.0)




-Non liver-related 13.0 (7.8-24.0)
Acute hepatitis 14.0 (10.3-23.8)
TIPS 4.0 (1.0-14.0)
Prior HE 5.0 (3.0-12.0)
Rifaximin 8.0 (3.0-15.0)
Use of other antibiotics 11.0 (5.0-21.0)
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other than rifaximin (10.5 days; p < 0.01) after controlling
for MELD score. Additionally HCV-infected patients had
shorter length of stay compared to patients without HCV
(-3.1 days; p < 0.01) after controlling for MELD score.
When we excluded patients who died during the
hospitalization, the median length of stay was 6 days (IQR:
3-13 days). As in the overall cohort, female gender, MELD
score, primary reason of hospitalization other than HE
and hepatitis C significantly influenced the length of stay.In addition, TIPS (-4.5 days; p < 0.04) and primary biliary
cirrhosis/primary sclerosing cholangitis (-8.3 days; p <
0.01) were associated with a shortened length of stay.
Discussion
Overall, clinical outcomes following a hospitalization for
hepatic encephalopathy in a tertiary care liver transplant
center were discouraging. Hospitalizations were long
with a median of 8 days but a maximum up to 113 days
and 33 patients (10.4%) hospitalized for longer than one
month. In-patient mortality and 30-day readmissions
were also frequent (20.9% and 38.6%, respectively). These
Table 3 Predictors of length of hospitalization
A. Overall cohort
Univariable analysis Multivariable analysis
Change in length of stay (days) p-value Change in length of stay (days) p-value







≤10 Reference . Reference .
11-20 -6.9 0.01 -5.4 <0.01
21-30 -1.8 0.59 -3.8 0.02
31-40 3.1 0.48 -2.9 0.15
>40 4.9 0.38 -2.5 0.33
Hepatitis B -0.2 0.95 . .
Hepatitis C -6.1 <0.01 -3.1 <0.01
Alcohol 1.0 0.53 . .
Non-alcoholic fatty liver disease 1.3 0.60 . .
Autoimmune hepatitis -1.4 0.73 . .
PBC/PSC 3.1 0.50 . .
Hemochromatosis -2.1 0.67 . .
Post-liver transplant complication 3.2 0.51 . .
Cryptogenic/unspecified 6.1 <0.01 . .
Reason of hospitalization
-HE Reference . Reference .
-Liver-related 9.8 <0.01 7.6 <0.01
-Non liver-related 12.9 <0.01 10.7 <0.01
Acute hepatitis 9.7 <0.01 . .
TIPS -3.5 <0.01 . .
Prior HE -3.7 0.01 . .
Rifaximin 1.9 0.28 . .
Use of other antibiotics 10.2 <0.01 10.5 <0.01
B. Survivors cohort
Univariable analysis Multivariable analysis
Change in length of stay (days) p-value Change in length of stay (days) p-value
Gender (female) 5.5 <0.01 3.4 0.01
Age





≤10 Reference Ref Reference Reference
11-20 -8.0 <0.01 -6.6 <0.01
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Table 3 Predictors of length of hospitalization (Continued)
21-30 -2.7 0.41 -5.1 <0.01
31-40 5.2 0.33 2.7 0.38
>40 15.6 0.13 3.0 0.52
Hepatitis B -4.1 <0.01 . .
Hepatitis C -6.1 <0.01 -3.9 <0.01
Alcohol 3.2 0.04 . .
Non-alcoholic fatty liver disease 2.7 0.30 . .
Autoimmune hepatitis -1.4 0.74 . .
PBC/PSC -8.2 0.01 -8.3 <0.01
Hemochromatosis -0.8 0.86 . .
Post-liver transplant complication 1.9 0.72 . .
Cryptogenic/unspecified 6.0 0.01 . .
Reason of hospitalization
-HE Reference Ref Reference Ref
-Liver-related 21.8 <0.01 10.3 <0.01
-Non liver-related 27.7 <0.01 15.9 <0.01
Acute hepatitis 16.0 <0.01 . .
TIPS -6.8 <0.01 -4.5 0.04
Prior HE -2.9 0.04 . .
Rifaximin -0.45 0.81 . .
Use of other antibiotics 9.4 <0.01 9.9 <0.01
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mortality rates of 14.1-15.6% and 30-day readmission
rates of 20% [2,6].
We identified potential predictors of longer length of
stay in our patient population. As expected, the length of
stay in patients was negatively associated with MELD.
Overall, patients with lower MELD had shorter length of
stay, except for patients with MELD <10. HE is rare in
patients with low MELD and hospitalization length may
have been driven by another cause than HE.
To our knowledge, no other studies on the association
between length of stay and infections or antibiotic use have
been published to date. Although antibiotic use is likely a
marker of sicker patients, it remains significant even after
adjustment for MELD score. The impact of antibiotics on
length of stay could originate from two pathways: a modifi-
cation of the gut flora induced by the antibiotics or as a
surrogate marker for infections. The latter is more prob-
able as infection is common in patients with advanced liver
disease and is a frequent trigger of HE [7].
In the past, infections have been associated with poor
outcomes in patients with HE. Hung et al. retrospectively
looked at 4,150 patients with HE and cirrhosis [8]. In a
Cox proportional-hazards regression model, they found a
significant association between the presence of a co-
existing infection and 30-day, 30-90-day and 90-day-1 year
mortality (HR: 1.66 (95% CI: 1.32-1.94), 1.51 (95% CI1.23-1.85), 1.34 (95% CI 1.13-1.58), respectively) while
adjusting for age, gender, HCV, variceal bleeding, ascites,
alcoholism, acute and chronic renal failure and peptic
ulcer bleeding [8]. In a recent prospective double-blind
randomized controlled trial comparing lactulose with pla-
cebo to lactulose with rifaximin, higher baseline leukocyte
count was associated with non-response to treatment [9].
Similarly, Sharma et al. found higher leukocyte counts
among non-lactulose responders than among responders,
but they did not find an association between infection and
non-response except for the occurrence of spontaneous
bacterial peritonitis and related leukocytes elevation to
systemic inflammation of patients with advanced liver
disease [10]. Shawcross et al. did not find any difference
in survival between patients with and without positive cul-
tures when they looked at 100 patients admitted to the in-
tensive care unit for HE [11].
Admission for HE was associated with a shorter length
of stay. It could be hypothesized that HE, as well as pos-
sible precipitants, were rapidly identified and treated in
these patients. Similarly, among survivors, patients with
TIPS had shorter length of stay. As HE is a frequent com-
plication of TIPS (median cumulative 1-year incidence:
10-50%), it was likely sought after and managed more ag-
gressively in these patients [12].
Patients with HCV liver disease had a shorter length of
stay than patients with non-HCV liver disease. The reason
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a slower and often more predictable progression of
HCV-induced liver disease compared to other liver con-
ditions. This is also supported by the fact that patients
with primary biliary cirrhosis/primary sclerosing cholan-
gitis, also slowly progressing diseases, had shorter lengths
of stay in the survivors multivariable analysis. Wiegand
et al. also evoked a difference in disease progression to
explain clinical differences observed in type of decompen-
sation between patients with alcoholic vs. non-alcoholic
liver diseases [13].
Conclusions
Female gender, hepatitis C infection, reason of admission,
MELD score and use of antibiotics are predictors of
length of stay. Because these characteristics are available
to the clinicians rapidly after patient admission, they can
be used to target interventions for patients at high risk
and reduce both length of stay and readmission. Even if
limited by their retrospective nature, our data are derived
from a large cohort of patients and include patients with
advanced liver disease (median MELD of 22).
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